SCYNEXIS, Inc.
P.O. Box 12878
Research Triangle Park
North Carolina
27709
United States
Tel: 919-544-8600
Fax: 919-544-8697
Website: http://www.scynexis.com/
Email: terry.marquardt@scynexis.com
330 articles about SCYNEXIS, Inc.
-
SCYNEXIS, Inc. Appoints Carole Sable, MD, As Chief Medical Officer
2/24/2014
-
SCYNEXIS, Inc. Receives Qualified Infectious Disease Product (QIDP) Designation From The FDA For Antifungal Agent SCY-078 For Oral Use
2/21/2014
-
SCYNEXIS, Inc. Appoints Vivian Doelling As Vice President Of Animal Health
11/20/2013
-
SCYNEXIS, Inc. Gains Worldwide Rights to Novel Antifungal Compound
5/30/2013
-
SCYNEXIS, Inc. Presents SCY-635 Data on HCV at International Liver Congress
4/25/2013
-
SCYNEXIS, Inc. and Immune Design Corporation Collaborate on Innovative Process for Vaccine Production Technology
4/10/2013
-
SCYNEXIS, Inc.'s Oral SCY-635 Shows Potential as an Immune Acting Antiviral to Augment Current HCV Treatments
11/12/2012
-
SCYNEXIS, Inc. to Report Phase 2a Study of SCY-635 for Treatment of HCV at American Association for Study of Liver Diseases
11/6/2012
-
SCYNEXIS, Inc. Announces Exclusive Licensing Deal for the Treatment of Canine Dry Eye
9/4/2012
-
SCYNEXIS, Inc. to Present on Screening Technology Used in Anti-Malarial Research at American Chemical Society National Meeting
8/20/2012
-
SCYNEXIS, Inc. Wants to Raise $25 Million by May
2/28/2012
-
Morria Biopharmaceuticals Plc Selects SCYNEXIS, Inc. to Support CMC Activities for MRX-4, a Novel Anti-Inflammatory Drug for Allergic Rhinitis
2/16/2012
-
MMV and SCYNEXIS, Inc. Offer 400 Active Compounds for Neglected Disease Drug Research at No Cost
12/19/2011
-
SCYNEXIS, Inc. Presents Data Demonstrating that SCY-635 Restores the Body’s Innate Immune Response to HCV and Could be an Effective Replacement for Recombinant Interferon
11/7/2011
-
SCYNEXIS, Inc. Release: Companies Collaborate to Provide Innovative Synthetic Process for Cancer Treatment Drug
11/2/2011
-
Innovative Vector Control Consortium Announces Discovery Project With SCYNEXIS, Inc.
7/12/2011
-
Anacor Pharmaceuticals, Inc. Partnership with SCYNEXIS, Inc. Advances Novel Drug Candidate to Combat Sleeping Sickness
6/29/2011
-
SCYNEXIS, Inc. and TB Alliance Sign HEOS Software Agreement
6/16/2011
-
Dr. Dennis Schmatz Joins SCYNEXIS, Inc. as Strategic Advisor
3/28/2011
-
SCYNEXIS, Inc. Receives Four Grants Under Federal Therapeutic Discovery Project Program
11/11/2010